Direkt zum Inhalt
Merck

F6800

Fenoldopam monohydrobromide

≥98%

Synonym(e):

6-Chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol monohydrobromide, SKF-82526

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen


Über diesen Artikel

Empirische Formel (Hill-System):
C16H16ClNO3 · HBr
CAS-Nummer:
Molekulargewicht:
386.67
UNSPSC Code:
12352200
PubChem Substance ID:
EC Number:
266-634-7
MDL number:
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

Produktname

Fenoldopam monohydrobromide, ≥98%

InChI key

DSGOSRLTVBPLCU-UHFFFAOYSA-N

InChI

1S/C16H16ClNO3.BrH/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21;/h1-4,7,13,18-21H,5-6,8H2;1H

SMILES string

ClC1=C(O)C(O)=CC2=C1CCNCC2C3=CC=C(O)C=C3.[H]Br

assay

≥98%

form

solid

storage condition

protect from light
under inert gas

color

off-white

solubility

DMSO: >12 mg/mL
H2O: 4.75 mg/mL

storage temp.

2-8°C

Gene Information

Biochem/physiol Actions

Fenoldopam is a selective dopamine agonist that is being considered for the parenteral treatment of systemic hypertension. In both an oral and parenteral form, fenoldopam causes peripheral vasodilation by stimulating dopamine-1 adrenergic receptors. Intravenous fenoldopam may provide advantages over sodium nitroprusside because it can induce both a diuresis and natriuresis, is not light sensitive, and is not associated with cyanide toxicity. There is no evidence for rebound hypertension after discontinuation of fenoldopam infusion.

Features and Benefits

This compound was developed by Hospira. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazardExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Sens. 1

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

T Hussain et al.
The American journal of physiology, 272(3 Pt 2), F339-F346 (1997-03-01)
The dopamine DA1 receptor transduces its signal via adenylyl cyclase and phospholipase C in the renal proximal tubule, which has been suggested to be defective at the level of receptor-G protein coupling in spontaneously hypertensive rats (SHR). We prepared basolateral
P A de Vries et al.
Journal of cardiovascular pharmacology, 34(2), 191-198 (1999-08-13)
The natriuretic response to a dopamine 1-like receptor agonist is blunted in spontaneously hypertensive rats (SHRs). Whether the renal vasodilator response to D1-like receptor stimulation in SHRs is defective also is unclear. To determine whether the renal hemodynamic response to
M Quevedo et al.
General pharmacology, 32(1), 123-125 (1999-01-15)
1. Fenoldopam mesylate, a benzazepine derivative, is a D1 receptor agonist that lowers blood pressure through vasodilation of renal, mesenteric, coronary and cerebral vascular beds. 2. Experiments were performed in rats, and mean carotid blood pressure and heart rate were
R A Hahn et al.
The Journal of pharmacology and experimental therapeutics, 223(2), 305-313 (1982-11-01)
SK&F 82526 (6-chloro-7,8-dihydroxy-1-(p-hydroxyphenyl)-2,3,4,5-tetrahydro-(1H)-3-benzazepine) was evaluated for its peripheral cardiovascular activity, effect on renal and central dopamine receptors and mechanism of action. Comparisons were made with dopamine. In anesthetized dogs, SK&F 82526 i.v., produced dose-related dilation of the renal vasculature, apparently
Adriano Caixeta et al.
Clinical and experimental pharmacology & physiology, 39(6), 497-505 (2012-05-31)
1. Contrast-induced nephropathy (CIN) often occurs after contrast media-related procedures and is associated with increased morbidity and mortality. The acute renal failure observed after administration of contrast media is usually transient but, in some cases, it can be severe enough

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung